Developer docs
API playgroundTry for free, no card

Search company profiles

IntraBio

Full company profile

uuid0000kzu

Namestring
IntraBio
Legal namestring
IntraBio Inc
Websiteurl
intrabio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases. Their clinical programs leverage the expertise of their scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developing small molecule drugs that modulate lysosomal function and intracellular calcium signaling. Their management team and business consultants have vast commercial and regulatory experience in drug product development, including all stages from small molecule manufacturing, clinical studies, and regulatory approvals in the USA and Europe. With their successful track record of drug development and commercialization, IntraBio’s team translates research in the fields of lysosomal biology, autophagy, and neurology into orphan drugs and treatments that will significantly improve the lives of patients, their caregivers, and families.

Short descriptiontext

IntraBio is a biopharmaceutical company.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, lysosomal storage disorders, neurodegenerative disease treatments, orphan drug development, specialty pharmaceuticals
Industry3 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AQNEURSA Product Sales
TypeOne Time License
Description

IntraBio generates revenue through the sale of AQNEURSA (levacetylleucine), an FDA-approved prescription drug for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. The company also received European Commission approval for AQNEURSA in the EU for adults and children aged 6 years and older weighing at least 20 kg.

intrabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1AQNEURSA prescription medication with patient support
ModelOtherBilling cadenceOther
Notes

AQNEURSA Cares provides financial assistance to eligible patients to reduce or eliminate out-of-pocket costs. Contact: 866-200-0419.

intrabio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IntraBio develops and commercializes AQNEURSA (levacetylleucine/IB1001), an FDA-approved orally administered modified amino acid therapy for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients. The company also pursues clinical development of the same active compound for Ataxia-Telangiectasia, GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease), and CACNA1A-related disorders, supported by AQNEURSA Cares patient financial assistance and an Expanded Access Program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 118% reduction in annual disease progression after 1 year of treatment as measured by 5-domain NPC Clinical Severity Scale
+2 more records
Product overview1 text field

IntraBio is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare neurodegenerative diseases. The company's lead product is AQNEURSA (levacetylleucine), which received FDA approval in September 2024 and European Commission approval in January 2026 for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). The investigational drug candidate IB1001 (N-acetyl-L-leucine/levacetylleucine) is the active ingredient in AQNEURSA and is also being developed for additional indications including Ataxia-Telangiectasia, GM2 Gangliosidosis, and CACNA1A-related disorders. The company operates an Expanded Access Program and AQNEURSA Cares patient support services.

Product and service1 record
1AQNEURSA (levacetylleucine)
CategoryRare Disease Therapeutics — Lysosomal Storage Disorder Treatment
Description

AQNEURSA is an FDA-approved and European Commission-approved orally administered, modified amino acid (N-Acetyl-L-Leucine) prescription therapy for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). It is approved for adults and pediatric patients weighing ≥15 kg in the US and adults and children aged 6 and older weighing at least 20 kg in the EU, with use as monotherapy or in combination with miglustat. The drug modulates lysosomal function and intracellular calcium signaling through bidirectional TFEB modulation and provides significant improvement in neurological symptoms and functioning within 12 weeks.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1EY
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-09-16
Description

IntraBio engaged EY to implement integrated finance managed services including SAP S/4HANA Cloud Private Edition platform, centralizing treasury, tax planning, procurement, and payments systems. EY estimates its solution reduced IntraBio's projected operating costs by nearly a third while positioning the company for efficient international growth across Europe, the Middle East, and Asia, and accelerating its IPO readiness.

ey.com
2University of Oxford
Strategic tierCoreTypeStrategic or Co-development Partner
Description

IntraBio's clinical programs leverage the expertise in lysosomal function and intracellular signaling of its scientific founders from the University of Oxford, including Professor Frances Platt and Professor Antony Galione. The company's platform technology results from decades of research at Oxford.

intrabio.com
3University of Munich (Ludwig Maximilians University)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

IntraBio's clinical programs leverage the expertise of its scientific founder Professor Michael Strupp from the University of Munich's Department of Neurology. Multiple clinical trials have been conducted with principal investigators from LMU Munich.

intrabio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1BioMarin Pharmaceutical
TypeDirect peer
Description

BioMarin is a global rare disease biopharmaceutical company with multiple approved enzyme replacement and gene therapies for ultra-rare conditions. It is directly comparable as a commercial-stage rare disease specialist with FDA-approved products and orphan drug designations across multiple indications.

2Ultragenyx Pharmaceutical
TypeDirect peer
Description

Ultragenyx is a commercial-stage rare disease company developing and commercializing therapies for rare and ultra-rare genetic diseases, including metabolic and neurological disorders. Comparable to IntraBio in business model (single platform applied across multiple rare indications) and orphan drug strategy.

3Alexion (AstraZeneca Rare Disease)
TypeBroad incumbent
Description

Alexion is a major rare disease franchise within AstraZeneca with multiple approved therapies for rare neurological and metabolic conditions. Comparable as a broader incumbent in the rare disease specialty pharma space with established commercial infrastructure for ultra-rare diseases.

4Recordati Rare Diseases
TypeBroad incumbent
Description

Recordati operates a dedicated rare diseases business unit focused on metabolic and neurological rare conditions, with established US and EU commercial infrastructure. Comparable as a broader incumbent rare disease specialty pharma with multi-region commercialization capabilities.

5Swedish Orphan Biovitrum (Sobi)
TypeBroad incumbent
Description

Sobi is a European-based specialty biopharma focused on rare diseases with a portfolio spanning immunology, genetics, and specialty care. Comparable as a broader incumbent with established rare disease commercialization infrastructure in both US and EU markets.

6Catalyst Pharmaceuticals
TypeDirect peer
Description

Catalyst Pharmaceuticals is a commercial-stage specialty pharma focused on rare neurological diseases, with FDA-approved therapies and a similar business model of focusing on ultra-rare conditions with high unmet medical need. Directly comparable in business model and patient population profile.

7Travere Therapeutics
TypeDirect peer
Description

Travere Therapeutics is a commercial-stage rare disease company developing therapies for rare neurological and metabolic disorders. Comparable as a similarly sized rare disease biopharma with FDA-approved products and a pipeline of orphan drug candidates.

8Denali Therapeutics
TypeEmerging player
Description

Denali Therapeutics is developing therapies for neurodegenerative diseases including lysosomal storage disorders, with a focus on crossing the blood-brain barrier. Comparable as an emerging player with overlapping therapeutic focus on neurodegenerative diseases and lysosomal biology.

9Homology Medicines
TypeEmerging player
Description

Homology Medicines is a genetic medicines company developing gene therapies for rare diseases including neurological and metabolic disorders. Comparable as an emerging player targeting the same lysosomal storage disorder space with a different therapeutic modality.

10Cyclo Therapeutics
TypeDirect peer
Description

Cyclo Therapeutics is a clinical-stage biopharmaceutical company developing treatments for Niemann-Pick disease type C and other rare diseases. Directly comparable as a competitor specifically focused on NPC and adjacent rare neurodegenerative indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IntraBio

Rare Disease Therapeuticsintrabio.com

IntraBio is a biopharmaceutical company.

What IntraBio does

IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases. Their clinical programs leverage the expertise of their scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developing small molecule drugs that modulate lysosomal function and intracellular calcium signaling. Their management team and business consultants have vast commercial and regulatory experience in drug product development, including all stages from small molecule manufacturing, clinical studies, and regulatory approvals in the USA and Europe. With their successful track record of drug development and commercialization, IntraBio’s team translates research in the fields of lysosomal biology, autophagy, and neurology into orphan drugs and treatments that will significantly improve the lives of patients, their caregivers, and families.

IntraBio firmographics

Firmographics
Name
IntraBio
Legal name
IntraBio Inc
Website
https://intrabio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
IntraBio is a biopharmaceutical company.
Ownership category
akta.pro rank

IntraBio industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Lysosomal storage disorders
  • Neurodegenerative disease treatments
  • Orphan drug development
  • Specialty pharmaceuticals

Where IntraBio is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IntraBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AQNEURSA Product Sales: IntraBio generates revenue through the sale of AQNEURSA (levacetylleucine), an FDA-approved prescription drug for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. The company also received European Commission approval for AQNEURSA in the EU for adults and children aged 6 years and older weighing at least 20 kg.

Pricing tiers

ModelBillingPrice
OtherOtherAQNEURSA prescription medication with patient support

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

IntraBio product offering

Product offering

Core offering

IntraBio develops and commercializes AQNEURSA (levacetylleucine/IB1001), an FDA-approved orally administered modified amino acid therapy for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients. The company also pursues clinical development of the same active compound for Ataxia-Telangiectasia, GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease), and CACNA1A-related disorders, supported by AQNEURSA Cares patient financial assistance and an Expanded Access Program.

Product overview

IntraBio is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare neurodegenerative diseases. The company's lead product is AQNEURSA (levacetylleucine), which received FDA approval in September 2024 and European Commission approval in January 2026 for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). The investigational drug candidate IB1001 (N-acetyl-L-leucine/levacetylleucine) is the active ingredient in AQNEURSA and is also being developed for additional indications including Ataxia-Telangiectasia, GM2 Gangliosidosis, and CACNA1A-related disorders. The company operates an Expanded Access Program and AQNEURSA Cares patient support services.

Differentiator

Problem solved

Functional benefit

Products and services

  • AQNEURSA (levacetylleucine) AQNEURSA is an FDA-approved and European Commission-approved orally administered, modified amino acid (N-Acetyl-L-Leucine) prescription therapy for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC). It is approved for adults and pediatric patients weighing ≥15 kg in the US and adults and children aged 6 and older weighing at least 20 kg in the EU, with use as monotherapy or in combination with miglustat. The drug modulates lysosomal function and intracellular calcium signaling through bidirectional TFEB modulation and provides significant improvement in neurological symptoms and functioning within 12 weeks.

Quantifiable outcome

  • 118% reduction in annual disease progression after 1 year of treatment as measured by 5-domain NPC Clinical Severity Scale
  • +2 more outcomes

Companies that use IntraBio

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

IntraBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

IntraBio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • EYcoreImplementation/ SI/ Consulting Partner · 16 September 2024IntraBio engaged EY to implement integrated finance managed services including SAP S/4HANA Cloud Private Edition platform, centralizing treasury, tax planning, procurement, and payments systems. EY estimates its solution reduced IntraBio's projected operating costs by nearly a third while positioning the company for efficient international growth across Europe, the Middle East, and Asia, and accelerating its IPO readiness.
  • University of OxfordcoreStrategic or Co-development PartnerIntraBio's clinical programs leverage the expertise in lysosomal function and intracellular signaling of its scientific founders from the University of Oxford, including Professor Frances Platt and Professor Antony Galione. The company's platform technology results from decades of research at Oxford.
  • University of Munich (Ludwig Maximilians University)coreStrategic or Co-development PartnerIntraBio's clinical programs leverage the expertise of its scientific founder Professor Michael Strupp from the University of Munich's Department of Neurology. Multiple clinical trials have been conducted with principal investigators from LMU Munich.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

IntraBio competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: BioMarin is a global rare disease biopharmaceutical company with multiple approved enzyme replacement and gene therapies for ultra-rare conditions. It is directly comparable as a commercial-stage rare disease specialist with FDA-approved products and orphan drug designations across multiple indications.
  • Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease company developing and commercializing therapies for rare and ultra-rare genetic diseases, including metabolic and neurological disorders. Comparable to IntraBio in business model (single platform applied across multiple rare indications) and orphan drug strategy.
  • Catalyst Pharmaceuticals: Catalyst Pharmaceuticals is a commercial-stage specialty pharma focused on rare neurological diseases, with FDA-approved therapies and a similar business model of focusing on ultra-rare conditions with high unmet medical need. Directly comparable in business model and patient population profile.
  • Travere Therapeutics: Travere Therapeutics is a commercial-stage rare disease company developing therapies for rare neurological and metabolic disorders. Comparable as a similarly sized rare disease biopharma with FDA-approved products and a pipeline of orphan drug candidates.
  • Cyclo Therapeutics: Cyclo Therapeutics is a clinical-stage biopharmaceutical company developing treatments for Niemann-Pick disease type C and other rare diseases. Directly comparable as a competitor specifically focused on NPC and adjacent rare neurodegenerative indications.

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Alexion is a major rare disease franchise within AstraZeneca with multiple approved therapies for rare neurological and metabolic conditions. Comparable as a broader incumbent in the rare disease specialty pharma space with established commercial infrastructure for ultra-rare diseases.
  • Recordati Rare Diseases: Recordati operates a dedicated rare diseases business unit focused on metabolic and neurological rare conditions, with established US and EU commercial infrastructure. Comparable as a broader incumbent rare disease specialty pharma with multi-region commercialization capabilities.
  • Swedish Orphan Biovitrum (Sobi): Sobi is a European-based specialty biopharma focused on rare diseases with a portfolio spanning immunology, genetics, and specialty care. Comparable as a broader incumbent with established rare disease commercialization infrastructure in both US and EU markets.

Emerging players

  • Denali Therapeutics: Denali Therapeutics is developing therapies for neurodegenerative diseases including lysosomal storage disorders, with a focus on crossing the blood-brain barrier. Comparable as an emerging player with overlapping therapeutic focus on neurodegenerative diseases and lysosomal biology.
  • Homology Medicines: Homology Medicines is a genetic medicines company developing gene therapies for rare diseases including neurological and metabolic disorders. Comparable as an emerging player targeting the same lysosomal storage disorder space with a different therapeutic modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

IntraBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IntraBio leadership team

Management profile

Number of profiles

Profiles7 records

IntraBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IntraBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IntraBio

What does IntraBio do?

IntraBio develops and commercializes AQNEURSA (levacetylleucine/IB1001), an FDA-approved orally administered modified amino acid therapy for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients. The company also pursues clinical development of the same active compound for Ataxia-Telangiectasia, GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease), and CACNA1A-related disorders, supported by AQNEURSA Cares patient financial assistance and an Expanded Access Program.

Is IntraBio a public or private company?

IntraBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was IntraBio founded?

IntraBio was founded in 2015. It employs 1 to 10 people.

Where is IntraBio based?

IntraBio is headquartered in Austin, United States, in the North America region.

How does IntraBio make money?

One revenue line is on record: AQNEURSA Product Sales.

Who are IntraBio's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Catalyst Pharmaceuticals, Travere Therapeutics and Cyclo Therapeutics. Broad incumbents are Alexion (AstraZeneca Rare Disease), Recordati Rare Diseases and Swedish Orphan Biovitrum (Sobi). Emerging players are Denali Therapeutics and Homology Medicines.

Does IntraBio have an API?

No public API is recorded for IntraBio.

What industry is IntraBio in?

IntraBio's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooShionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global PortfolioShionogi completed its acquisition of IntraBio, paying $2 billion for AQNEURSA and rare disease capabilities. AQNEURSA is FDA-approved for Niemann-Pick disease type C and ataxia in Ataxia-Telangiectasia, with EMA approval for NPC. The company will continue IntraBio's programs and explore additional rare disease indications.Business Wire BlogShionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global PortfolioShionogi completed its acquisition of IntraBio for $2 billion, adding AQNEURSA to its rare disease portfolio. AQNEURSA is approved in the U.S. and Europe for Niemann-Pick disease type C and is the first treatment for ataxia in Ataxia-Telangiectasia. The company will continue IntraBio's programs and explore additional indications.FinancialContent Business PageShionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global PortfolioShionogi completed its acquisition of IntraBio, paying $2 billion for all outstanding shares, adding AQNEURSA to its rare disease portfolio. AQNEURSA is FDA-approved for Niemann-Pick disease type C and ataxia in ataxia-telangiectasia, with EMA approval pending. Shionogi will continue IntraBio's programs and explore additional indications.FinanzNachrichten.deShionogi Inc.: Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA (levacetylleucine) to Growing Rare Disease Global PortfolioShionogi completed its acquisition of IntraBio, paying $2.0 billion for all outstanding shares. The deal adds AQNEURSA, approved in the U.S. and Europe for Niemann-Pick disease type C and as the first treatment for ataxia in Ataxia-Telangiectasia. Shionogi will continue IntraBio's programs and explore additional rare disease indications.YahooCan Shionogi (TSE:4507) Support Its Price With Earnings After IntraBio?Shionogi's stock trades at an 8.9x P/E, below the pharmaceuticals industry average of 13.8x, while a planned $2B acquisition of IntraBio could reshape its neurological portfolio. The Fair Ratio model suggests the current valuation is undervalued, though the earnings base must support the expanded rare disease pipeline.GenengnewsShionogi Grows Rare Disease Portfolio with $2B IntraBio AcquisitionShionogi agreed to acquire IntraBio for $2 billion to expand its rare disease portfolio with Aqneursa, a drug for Niemann-Pick disease type C and ataxia-telangiectasia. The FDA approved Aqneursa for ataxia-telangiectasia in September 2024, and the deal is expected to close this quarter.BioSpaceShionogi makes $2B rare disease play with IntraBio buyShionogi agreed to acquire IntraBio for $2 billion upfront, weeks after the biotech received FDA approval for Aqneursa in Niemann-Pick disease type C and ataxia-telangiectasia. The drug's net sales last year were $68 million, with analysts estimating $1 billion in global peak sales. Shionogi's rare disease portfolio is anchored by Radicava.Pharmaceutical TechnologyShionogi bolsters rare disease portfolio with $2bn IntraBio buyout - Pharmaceutical TechnologyShionogi will acquire IntraBio for $2bn, adding Aqneursa to its portfolio. Aqneursa, approved in 2024 for Niemann Pick disease type C, also received EU and FDA approvals for ataxia-telangiectasia. The deal aims to expand Shionogi's rare disease presence.MedCity NewsShionogi Adds to Its Rare Disease Strategy With $2B IntraBio AcquisitionShionogi acquired IntraBio for $2 billion, adding levacetylleucine (Aqneursa) to its rare disease portfolio. The drug, approved for Niemann-Pick disease type C and expanded for ataxia-telangiectasia, generated $67.8 million in fiscal 2025 revenue. The deal is expected to close by year-end.QuartzShionogi acquires rare disease startup IntraBio for $2 billionShionogi agreed to acquire IntraBio for $2 billion, adding Aqneursa and neurodegenerative disease programs. Aqneursa is approved for Niemann-Pick disease type C and ataxia, with IntraBio reporting $68 million in 2025 sales. The deal is expected to close between November and December.